The Oxipurity 4000 line comprises a variety of pharmaceutical grade polyethylene glycols that, according to the partners, can be used for binding, as plasticizer, solubilizer and lubricant in several pharmaceutical dosage forms.

Daniel Burchart, board member Life Sciences of Harke Group and managing director of Harke Pharma said: “We are proud that we could establish a cooperation with Oxiteno, the leading producer of PEGs in the Americas. The Oxipurity range in pharmaceutical quality is complementary to our portfolio of excipients and APIs. The joint efforts of Oxiteno and Harke Pharma will be the basis for the commercial success in several parts of Europe. Within Harke Group we already cooperate with Oxiteno in other business fields as, e.g., crop solutions.”

Fabiana Marra, global head of Performance Products, added: “Oxiteno is continuously working to expand its Nutrition & Health portfolio to support the challenges our clients face and offer solutions and new tools to address society’s evolving health, nutrition and care needs. Europe is a key market for our Pharma business, and partnering with Harke, a strong distributor and services provider for the pharmaceuticals industry, offers great opportunities for our Oxipurity products, and great benefits for clients and their formulations.”